Risk Factors for and Clinical Outcome of Congenital Cytomegalovirus Infection in a Peri-Urban West-African Birth Cohort

listen audio

Study Justification:
– Congenital cytomegalovirus (CMV) infection is a prevalent congenital infection worldwide, but there is limited data on its epidemiology and clinical outcomes in developing countries.
– Understanding the risk factors for transmission and clinical outcomes of CMV infection in developing countries is important for public health interventions and prevention strategies.
Study Highlights:
– The study was conducted in a peri-urban West-African birth cohort in The Gambia.
– The prevalence of congenital CMV infection in this cohort was 5.4%, which is higher than previously reported in industrialized countries.
– Risk factors for congenital CMV infection included being a first-born baby, being born in crowded compounds, and having active placental malaria infection.
– Congenitally infected children did not show obvious clinical implications during the first year of life.
– The high burden of other infections in the environment may have mitigated the effect of early life CMV infection on the developing infant.
Study Recommendations:
– Public health interventions should focus on preventing and reducing the transmission of CMV infection, especially in populations with high prevalence rates.
– Strategies to reduce crowded living conditions and prevent placental malaria infection may help reduce the risk of congenital CMV infection.
– Further research is needed to understand the long-term clinical implications of congenital CMV infection in developing countries.
Key Role Players:
– Researchers and scientists involved in studying congenital infections and public health in developing countries.
– Healthcare providers and policymakers responsible for implementing prevention strategies and interventions.
– Community leaders and organizations involved in promoting health and well-being in peri-urban areas.
Cost Items for Planning Recommendations:
– Research funding for conducting further studies on congenital CMV infection in developing countries.
– Resources for implementing public health interventions, such as educational campaigns and access to healthcare services.
– Investments in improving living conditions and reducing the burden of other infections in the environment.

The strength of evidence for this abstract is 7 out of 10.
The evidence in the abstract is moderately strong. The study provides data from a birth cohort in The Gambia, which is a developing country with a high burden of infectious diseases. The study collected urine samples from term infants and tested them for CMV DNA. Risk factors for transmission and clinical outcomes were assessed, including placental malaria infection. The study found a prevalence of congenital CMV infection of 5.4% and identified associations with first-born status, crowded living conditions, and active placental malaria. However, the study did not find any obvious clinical implications during the first year of life. To improve the strength of the evidence, future studies could consider increasing the sample size and conducting a longer follow-up period to assess long-term clinical outcomes. Additionally, including a control group of non-infected infants would provide a comparison for evaluating the impact of congenital CMV infection.

Background: Congenital cytomegalovirus (CMV) infection is the most prevalent congenital infection worldwide. Epidemiology and clinical outcomes are known to vary with socio-economic background, but few data are available from developing countries, where the overall burden of infectious diseases is frequently high. Methodology/Principal Findings: As part of an ongoing birth cohort study in The Gambia among term infants, urine samples were collected at birth and tested by PCR for the presence of CMV DNA. Risk factors for transmission and clinical outcome were assessed, including placental malaria infection. Babies were followed up at home monthly for morbidity and anthropometry, and at one year of age a clinical evaluation was performed. The prevalence of congenital CMV infection was 5.4% (40/741). A higher prevalence of hepatomegaly was the only significant clinical difference at birth. Congenitally infected children were more often first born babies (adjusted odds ratio (OR) 5.3, 95% confidence interval (CI) 2.0-13.7), more frequently born in crowded compounds (adjusted OR 2.9, 95%CI 1.0-8.3) and active placental malaria was more prevalent (adjusted OR 2.9, 95%CI 1.0-8.4). These associations were corrected for maternal age, bed net use and season of birth. During the first year of follow up, mothers of congenitally infected children reported more health complaints for their child. Conclusions/Significance: In this study, the prevalence of congenital CMV among healthy neonates was much higher than previously reported in industrialised countries, and was associated with active placental malaria infection. There were no obvious clinical implications during the first year of life. The effect of early life CMV on the developing infant in the Gambia could be mitigated by environmental factors, such as the high burden of other infections. © 2007 van der Sande et al.

In January 2002, a birth cohort was initiated in the village of Sukuta, The Gambia, approximately 15 km away from the Medical Research Council (MRC) Laboratories in Fajara, in order to study the epidemiological, clinical, immunological and virological determinants of early life CMV infection in an endemic environment. The wider objective of this cohort was to understand how the immune system of the foetus and new born develops in relation to CMV and other early life infections, and how this interacts with the response to vaccinations. Sukuta has approximately 25,000 inhabitants, and is adjacent to, but distinct from the nearby expanding peri-urban community centred around the village of Serrekunda between the capital Banjul 20 km to the north and a growing urban centre (Brikama) 25 km to the south. A variety of ethnic groups live in the village, although the Mandinka group make up about half of the population. Eligible for recruitment in the cohort were children born in the health centre of the study village whose parents gave informed consent. Babies whose mothers had suffered a serious infectious disease during pregnancy for which they had been admitted were not recruited. Pre-term babies, babies born with a serious congenital deficit, or babies who were in need for a transfer to a referral hospital immediately following delivery, were not included either. Routine follow up was conducted monthly. During these routine visits, anthropometric measurements and a morbidity checklist were completed. Vaccinations were given according to the Gambia Government schedule. Recruitment and follow-up are still ongoing. Urine was collected within two weeks of birth and transported to the laboratory within 24 hours, and stored at −20°C. CMV DNA was detected by an in-house nested PCR method amplifying a region of the UL50 gene. Frequent negative controls (one in seven reactions) were included to minimise the risk of false-positive reactions. CMV viral load in maternal samples collected at the time of delivery (vagina, urine, saliva, colostrum and plasma) from a sub-set of mothers was quantified by real-time PCR. The lower limit of detection by real-time PCR was 100 copies/ml for plasma and vaginal swab, and 50 copies/ml for the other samples. Maternal plasma levels of CMV-specific IgG were detected and quantified using commercial enzyme immunoassays (DiaSorin, Saluggia, Italy) used according to the manufacturer’s instructions. The complete results from maternal testing will be described in a subsequent viroimmunology paper. Immediately upon delivery, a placental imprint was made on a glass slide. Slides were Giemsa stained, and transported to the laboratory for the detection of parasitaemia. Slides were read by a trained microscopist for the speciation and quantification of malaria parasites; and a random selection of slides was read by a second trained microscopist to assure quality control. At least 100 fields were read before a negative result was declared. A placental biopsy was taken and immediately placed into 10% formalin for transport to the laboratory. Each placental sample was embedded in paraffin wax, sectioned and stained with standard H&E stain. Slides were examined under a light microscope for evidence of malaria infection according to the classification described by Ismail et al. [20]. Thus placentas were ascribed to one of 4 groups: no infection, acute infection (parasites in the intervillous space), chronic infection (parasites and malaria pigment) or past infection (pigment only). A paediatric assessment, including a neurological examination of the child was performed at birth by a qualified paediatrician (first OO, later MP), at which time the CMV status of the baby was not yet known. Baseline data were collected at birth, and every month, morbidity data and anthropometry was collected in a standardised way. Parents could consult the paediatrician with any complaints or concerns about their children’s health and welfare throughout the follow up period, and at one year of age another standardised clinical evaluation was performed by the paediatrician. Maternal height and weight were measured six months after delivery. Congenital CMV was defined as the detection of CMV in the urine by PCR within two weeks of birth. Acute malaria infection was defined as the detection of malaria parasites by microscopy, or the detection of an acute infection by histology. Active malaria infection was defined as a histological diagnosis of acute or chronic infection. Field, clinic and laboratory data were all merged and validated in a relational Microsoft Access database. Data were analysed using Stata 8 (Stata Corp, Texas, USA). Statistical significance was assigned when a p-value<0.05 was obtained. Differences in proportions were compared with a chi-squared test. Univariate logistic regression analysis was used to calculate odds ratio's (ORs) to test for significance of associations between risk factors and congenital CMV infection. Where needed, variables were dichotomised or categorised to enable inclusion in a logistic regression analysis. Risk factors were included in a stepwise backward multivariate model if p<0.1 to obtain independent adjusted ORs. The study was approved by the Gambia Government/MRC Ethics Committee. All parents gave written informed consent for their child to participate.

N/A

Based on the provided information, here are some potential innovations that could be used to improve access to maternal health:

1. Mobile Clinics: Implementing mobile clinics that can travel to peri-urban areas, such as the village of Sukuta in The Gambia, to provide maternal health services. This would ensure that pregnant women have access to prenatal care, screenings, and vaccinations without having to travel long distances.

2. Telemedicine: Introducing telemedicine services that allow pregnant women in remote areas to consult with healthcare professionals through video calls. This would enable them to receive medical advice, guidance, and support without the need for physical travel.

3. Community Health Workers: Training and deploying community health workers in peri-urban communities to provide basic maternal health services, including education on prenatal care, nutrition, and hygiene practices. These workers can also conduct regular check-ups and screenings, ensuring early detection and intervention for any potential health issues.

4. Health Education Programs: Developing and implementing health education programs specifically targeting pregnant women and their families in peri-urban areas. These programs can focus on raising awareness about the importance of prenatal care, vaccinations, and healthy lifestyle choices during pregnancy.

5. Improved Transportation: Enhancing transportation infrastructure in peri-urban areas to facilitate easier access to healthcare facilities. This could involve improving road networks, providing public transportation options, or establishing partnerships with ride-sharing services to offer discounted or free transportation for pregnant women.

6. Collaborative Partnerships: Establishing partnerships between local healthcare providers, research institutions, and government agencies to share resources, knowledge, and expertise. This collaboration can lead to the development of targeted interventions and policies that address the specific challenges faced by pregnant women in peri-urban areas.

These innovations aim to address the barriers to accessing maternal health services in peri-urban areas, ultimately improving the health outcomes for both mothers and their infants.
AI Innovations Description
Based on the provided information, here is a recommendation that can be developed into an innovation to improve access to maternal health:

Title: Mobile Health Clinics for Maternal Health Services

Description: In order to improve access to maternal health services, a recommendation is to implement mobile health clinics in peri-urban and rural areas. These clinics can provide essential maternal health services, including prenatal care, postnatal care, and family planning, directly to communities that may have limited access to healthcare facilities.

The mobile health clinics can be equipped with trained healthcare professionals, medical equipment, and supplies necessary for providing comprehensive maternal health services. They can travel to different locations on a regular schedule, ensuring that pregnant women and new mothers have access to the care they need without having to travel long distances.

By bringing maternal health services closer to the communities, mobile health clinics can help reduce barriers to access, such as transportation costs and distance. This innovation can also address the issue of limited healthcare infrastructure in peri-urban and rural areas.

Additionally, the mobile health clinics can be used as a platform for health education and awareness campaigns, providing information on topics such as prenatal care, nutrition, breastfeeding, and family planning. This can empower women with knowledge and enable them to make informed decisions about their health and the health of their children.

Implementing mobile health clinics for maternal health services can be a cost-effective and efficient way to reach underserved populations and improve access to essential care. It is important to collaborate with local communities, healthcare providers, and government agencies to ensure the successful implementation and sustainability of this innovation.
AI Innovations Methodology
To improve access to maternal health, here are some potential recommendations:

1. Mobile Clinics: Implementing mobile clinics that can travel to remote areas and provide essential maternal health services such as prenatal care, vaccinations, and postnatal care.

2. Telemedicine: Utilizing telemedicine technology to connect pregnant women in rural areas with healthcare professionals who can provide virtual consultations, monitor their health remotely, and offer guidance and support.

3. Community Health Workers: Training and deploying community health workers who can provide basic maternal health services, education, and referrals in underserved areas.

4. Transportation Support: Establishing transportation systems or subsidies to help pregnant women in remote areas access healthcare facilities for prenatal visits, delivery, and emergency care.

5. Maternal Health Education: Developing and implementing comprehensive maternal health education programs that target women and their families, providing information on prenatal care, nutrition, hygiene, and warning signs during pregnancy.

To simulate the impact of these recommendations on improving access to maternal health, a methodology could include the following steps:

1. Define the baseline: Gather data on the current state of maternal health access in the target area, including the number of healthcare facilities, distance to facilities, and utilization rates.

2. Identify key indicators: Determine the key indicators that will be used to measure the impact of the recommendations, such as the number of prenatal visits, percentage of deliveries attended by skilled birth attendants, and maternal mortality rates.

3. Establish a control group: Select a control group that represents the current situation without the implementation of the recommendations. This group will serve as a comparison to measure the impact of the interventions.

4. Implement the recommendations: Introduce the recommended interventions, such as mobile clinics, telemedicine, community health workers, transportation support, and maternal health education programs.

5. Monitor and collect data: Continuously monitor the implementation of the interventions and collect data on the selected indicators. This can be done through surveys, interviews, and medical records.

6. Analyze the data: Compare the data collected from the intervention group with the control group to assess the impact of the recommendations. Use statistical analysis to determine if there are significant improvements in the selected indicators.

7. Evaluate the results: Assess the findings to determine the effectiveness of the recommendations in improving access to maternal health. Identify any challenges or limitations encountered during the implementation process.

8. Adjust and refine: Based on the evaluation results, make any necessary adjustments or refinements to the interventions to further enhance their impact on improving access to maternal health.

By following this methodology, it will be possible to simulate the impact of the recommendations on improving access to maternal health and make informed decisions on scaling up successful interventions.

Share this:
Facebook
Twitter
LinkedIn
WhatsApp
Email